Aligos Therapeutics Presents Breakthrough Findings at International HBV Meeting
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a highly regarded clinical-stage biopharmaceutical company, has brought attention to its innovative research with the announcement of six significant preclinical presentations scheduled for the International HBV Meeting. This event, focused on hepatic and viral diseases, will showcase compelling topics from September 8 to 12, 2025.
The company’s efforts revolve around enhancing patient care through next-generation therapies. This commitment is manifested in their presentations, which explore novel mechanisms of action, advancements in treatment strategies, and potential cures for viral infections. Notably, researchers will discuss a pioneering antisense oligonucleotide (ASO) approach targeting the hepatitis delta virus (HDV).
Advancements in HBV Treatment Strategies
Aligos is particularly enthusiastic about presenting its findings related to ALG-000184, a product showing promise in reducing HBV cccDNA. "We are excited to share our ongoing Phase 2 B-Supreme study results that underscore the efficacy of ALG-000184 in a preclinical setting. Preliminary data aligns well with clinical observations of reduced HBV antigen levels in treated patients," explained Lawrence Blatt, PhD, MBA, Chairman, President, and CEO of Aligos Therapeutics.
The research not only reaffirms ALG-000184's direct actions on the Hepatitis B virus but also emphasizes its secondary mechanisms that can further benefit patients. Aligos is adamant about the potential this drug has in the fight against chronic HBV infection while also making strides in targeting HDV co-infection, a condition that complicates and accelerates liver disease progression.
Overview of Presentations
Aligos will be presenting a diverse range of papers as part of its commitment to sharing knowledge and advancing research in the field:
- Paper #: 52
Type: Oral Presentation
Title: The CAM-E ALG-001075 potently reduces HBV cccDNA in preclinical experiments
Presenter: Yannick Debing, PhD
Date/Time: September 11, 2025, 10:30 AM – 12:00 PM CET
Session: Therapy II - Paper #: 53
Type: Oral Presentation
Title: Antisense oligonucleotide-based strategy to target hepatitis delta virus infections
Presenter: Julie Lucifora, PhD
Date/Time: September 11, 2025, 10:30 AM – 12:00 PM CET
Session: Therapy II - Paper #: 2
Type: Oral Presentation
Title: A Syrian hamster model of persistent HDV infection
Presenter: Elias Broeckhoven
Date/Time: September 8, 2025, 5:00 PM – 6:30 PM CET
Session: Molecular Virology I - Paper #: 283
Type: Poster Presentation
Title: Differential impact of CAM-E and CAM-A on hepatitis B core protein phosphorylation states in vitro
Presenter: Hannah Vanrusselt
Date/Time: September 10, 2025, 11:00 AM – 12:00 PM CET
Session: Poster Session II - Paper #: 285
Type: Poster Presentation
Title: Capsid assembly modulators bind and directly target HBeAg
Presenter: Jordi Verheyen
Date/Time: September 10, 2025, 11:00 AM – 12:00 PM CET
Session: Poster Session II - Paper #: 127
Type: Poster Presentation
Title: PML nuclear bodies store aggregated HBc and reduce CAM-induced apoptosis in HBc-expressing cells
Presenter: Vaclav Janovec, PhD
Date/Time: September 8, 2025, 5:00 PM – 6:30 PM CET
Session: Molecular Virology
Company Overview and Future Directions
Aligos Therapeutics, Inc. stands at the forefront of innovation in biotechnology, driven by a determination to meet the unmet medical needs of patients suffering from liver and viral diseases. With a dedicated pipeline focused on chronic hepatitis B virus (HBV), metabolic dysfunctions such as steatohepatitis, and emerging threats like coronaviruses, Aligos paints a promising picture for the future of therapeutic development.
The company maintains its commitment to pushing forward in its research and is optimistic about the potential impact its discoveries may have on treating these challenging conditions. For ongoing updates and insights, please visit the official Aligos website, which will also host the posters and presentations from the HBV Meeting following the event.
Frequently Asked Questions
What is the focus of Aligos Therapeutics?
Aligos Therapeutics specializes in developing therapies for liver and viral diseases, particularly focusing on conditions like hepatitis B and C.
Where will Aligos present its research findings?
The research will be presented at the International HBV Meeting held from September 8-12, 2025.
What are ALGS’s significant products?
ALGS’s notable product includes ALG-000184, which is showing promise in reducing HBV cccDNA levels.
Are there any strategies targeting hepatitis delta virus?
Yes, Aligos is employing an antisense oligonucleotide strategy to potentially cure hepatitis delta virus infections.
How can investors learn more about Aligos?
Investors can find more information on the Aligos website or through direct contact with their investor relations representatives.
